Incannex Healthcare has been granted a pre-investigational new drug (IND) meeting with the US Food and Drug Administration (FDA) regarding progressing the company’s hydroxychloroquine/CBD drug cocktail IHL-675A in preventing acute respiratory distress syndrome (ARDS) and sepsis associated acute respiratory distress syndrome (SAARDS).

ARDS is a life-threatening injury characterised by fluid leakage on the lungs while SAARDS is often a deadly side effect of Covid-19.

The aim of the meeting is to obtain regulatory guidance and agreement on the most efficient clinical development plan before Incannex submits its IND application for IHL-675A. The FDA told Incannex it plans to comment on its development proposal by April 21, 2021.

Prior to launching Cannabiz, Martin was co-founder and CEO of Asia-Pac’s leading B2B media and marketing information brand Mumbrella, overseeing its sale to Diversified Communications in 2017. A journalist...

Leave a comment